Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL855342 | 1.00 | GSR (0.52) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1310240 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3088558 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1323618 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL3088557 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1309368 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1309450 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL2131918 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1308683 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 | |
| SCHEMBL1308718 | 0.98 | GSR (0.50) | GSRCPB2GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| CN-116606405-A | Anisotropic hydrogel material and preparation method thereof | 沧州市天津工业大学研究院 | 2023-08-18 | — | — | CN | claimed |
| EP-2167103-B1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS | ALLEXCEL INC (US) | 2017-03-01 | — | — | EP | claimed |
| CN-101636169-B | Self-assembling amphiphilic polymers as antiviral agents | ALLEXCEL INC | 2014-05-07 | — | — | CN | claimed |
| WO-2013120610-A2 | ANTIMICROBIAL FILLER MATERIAL MIXTURE | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2013-08-22 | — | — | WO | claimed |
| WO-2013029790-A2 | DENTAL FILLING MATERIAL MIXTURE FOR FILLING ROOT CANALS | HEINRICH-HEINE-UNIVERSITÄT DÜSSELDORF (DE) | 2013-03-07 | — | — | WO | claimed |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | disclosed |
| US-20250262335-A1 | PSMA-Targeting Ligands with Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2025-08-21 | — | — | US | disclosed |
| US-12318458-B2 | PSMA-targeting ligands with optimal properties for imaging and therapy | WISCONSIN ALUMINI RESEARCH FOUNDATION (US) | 2025-06-03 | — | — | US | disclosed |
| CN-119470406-A | Phthalic dicarboxaldehyde disinfectant concentration detection test paper and preparation method thereof | 山东新华莎罗雅生物技术有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20250009895-A1 | DRUG LOADING MONOMOLECULAR NANO POLYMER, PRODRUG, MICELLE, DRUG DELIVERY SYSTEM, PREPARATION METHOD, AND USE | JIAXING QINGZHUN MEDI-TECH CO., LTD (CN) | 2025-01-09 | — | — | US | disclosed |
| US-12156921-B2 | PSMA-targeting ligands with optimal properties for imaging and therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2024-12-03 | — | — | US | disclosed |
| WO-2000032611-A1 | CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION | MONSANTO TECHNOLOGY LLC (US) | 2000-06-08 | — | — | WO | disclosed |
| EP-1003561-A2 | LATENT REACTIVE POLYMERS WITH BIOLOGICALLY ACTIVE MOIETIES | SurModics, Inc. (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | disclosed |
| WO-1999008717-A2 | LATENT REACTIVE POLYMERS WITH BIOLOGICALLY ACTIVE MOIETIES | SURMODICS, INC. (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
| US-4784961-A | NITROAMINO BENZOXADIAZOLE DERIVATIVE FLUORESCENT COMPOUNDS | ABBOTT LABORATORIES (US) | 1988-11-15 | — | — | US | disclosed |
| EP-0174162-A2 | Pharmaceutically active dipeptide derivatives | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262335-A1 | PSMA-Targeting Ligands with Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | GSR 3371/4885CPB2 361/4885GNAI3 1599/4885 |
| US-20250009895-A1 | DRUG LOADING MONOMOLECULAR NANO POLYMER, PRODRUG, MICELLE, DRUG DELIVERY SYSTEM, PREPARATION METHOD, AND USE | LPXN, SLC7A5, SLC43A1 | GSR 3317/4885CPB2 2488/4885GNAI3 3637/4885 |
| US-12318458-B2 | PSMA-targeting ligands with optimal properties for imaging and therapy | PSMA1, PSMA2, FOLH1 | GSR 3371/4885CPB2 361/4885GNAI3 1599/4885 |
| US-12156921-B2 | PSMA-targeting ligands with optimal properties for imaging and therapy | PSMA1, PSMA2, FOLH1 | GSR 3371/4885CPB2 361/4885GNAI3 1599/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | GSR 4108/4885CPB2 1744/4885GNAI3 2822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.